Biomerica Inc. (NASDAQ:BMRA) saw its stock climb 7% in premarket trading Wednesday after announcing that the United Arab Emirates Ministry of Health and Prevention has granted approval for its Fortel Kidney Test for home use.
The test is designed to detect low levels of albumin in urine, an early indicator of kidney disease, in just 10 minutes. It is particularly aimed at individuals with diabetes and hypertension, who face a higher risk of developing chronic kidney disease.
This regulatory approval opens a substantial market opportunity in the UAE, where roughly one in four nationals has diabetes and about 31% of the population suffers from hypertension, according to a meta-analysis cited by the company.
“The Fortel Kidney Test addresses a gap in preventative healthcare by allowing patients and physicians to detect kidney disease before symptoms appear,” said Zack Irani, CEO of Biomerica. “With the high prevalence of diabetes and hypertension in the UAE, this approval supports our mission to bring life-saving diagnostic tools to communities where they are most needed.”
Biomerica plans to distribute the test through pharmacies, clinics, and hospitals across the UAE, leveraging partnerships with healthcare providers and distributors. The approval strengthens the company’s presence in the Middle East, following regional success with its EZ Detect Colon Disease Test.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.